NASDAQ$SMLR
Semler Scientific Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Semler Scientific reported record quarterly revenues and pre-tax net income, driven by sales of QuantaFlo® for peripheral arterial disease testing. The company is focused on developing its business in heart dysfunction.
Semler Scientific reported a 25% increase in revenue to $18.6 million and a 44% increase in net income to $5.9 million for Q2 2023 compared to the corresponding period in 2022. The company achieved record quarterly revenues and pre-tax net income, primarily from sales of QuantaFlo®.
- Revenue was $18.6 million, an increase of 25% compared to the corresponding period of 2022
- Net income was $5.9 million, an increase of 44% compared to the corresponding period of 2022
- Cash, cash equivalents and short-term investments of $51.8 million
- Highest quarterly revenues and pre-tax net income since inception
Headline financials
Revenue & EPS history
Semler Scientific · Revenue · Quarterly
$18.6M
Forward guidance
This press release contains forward-looking statements regarding the development of business in heart dysfunction and diabetes, continued testing of asymptomatic patients, and the benefits of early identification of at-risk patients.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
-0.2%
Avg return
Earnings day
-2.4%
Avg return
5 days after
-5.8%
Avg return
30 days after
54%
25 / 46 earnings
Positive
+33.6%
Q4 2014
Best reaction
-33.3%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -10.7% | -16.0% | -25.1% | |
| Q2 2025 | -1.8% | +2.0% | -20.7% | |
| Q1 2025 | -11.4% | +17.9% | -19.3% | |
| Q4 2024 | +3.0% | -12.4% | -22.7% | |
| Q3 2024 | +27.1% | +29.9% | +106.6% | |
| Q2 2024 | -5.4% | -1.7% | -16.7% | |
| Q4 2023 | -32.7% | -36.8% | -42.5% | |
| Q3 2023 | +7.6% | — | — | |
| Q2 2023 | +7.9% | — | — | |
| Q1 2023 | +13.8% | — | — | |
| Q4 2022 | +26.9% | — | — | |
| Q3 2022 | -33.3% | — | — | |
| Q2 2022 | +19.4% | — | — | |
| Q1 2022 | -20.6% | — | — | |
| Q4 2021 | -27.3% | — | — | |
| Q3 2021 | -25.6% | — | — | |
| Q2 2021 | -2.7% | — | — | |
| Q1 2021 | +1.5% | — | — | |
| Q4 2020 | +13.6% | — | — | |
| Q3 2020 | +10.0% | — | — | |
| Q2 2020 | -3.6% | — | — | |
| Q1 2020 | -2.6% | — | — | |
| Q4 2019 | +1.8% | — | — | |
| Q3 2019 | +1.7% | — | — | |
| Q2 2019 | +1.5% | — | — | |
| Q1 2019 | -2.7% | — | — | |
| Q4 2018 | +4.8% | — | — | |
| Q3 2018 | -12.5% | — | — | |
| Q2 2018 | +20.6% | — | — | |
| Q1 2018 | +6.4% | — | — | |
| Q4 2017 | +2.5% | — | — | |
| Q3 2017 | +16.0% | — | — | |
| Q2 2017 | -5.9% | — | — | |
| Q1 2017 | +1.5% | — | — | |
| Q4 2016 | +7.9% | — | — | |
| Q3 2016 | -16.0% | — | — | |
| Q2 2016 | +8.1% | — | — | |
| Q1 2016 | -9.2% | — | — | |
| Q4 2015 | -7.9% | — | — | |
| Q3 2015 | +0.1% | — | — | |
| Q2 2015 | -12.2% | — | — | |
| Q1 2013 | +0.9% | — | — | |
| Q4 2014 | +33.6% | — | — | |
| Q3 2014 | -3.7% | — | — | |
| Q2 2014 | -2.0% | — | — | |
| Q1 2014 | +1.2% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro